FDA authorizes, with special controls, direct-to-consumer test that reports three mutations in the BRCA breast cancer genes

FDA has authorized 23andMe to market a consumer test that reports only 3 out of more than 1,000 known mutations in BRCA genes

Food and Drug Recall.org